Centogene to Open New Lab for COVID-19 Testing
The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.
Centogene, a Germany-based commercial-stage company focused on rare diseases, announced on April 15, 2020 that it will open a new laboratory in Hamburg, Germany to increase testing capacity for COVID-19.
The lab facilities and equipment were acquired from Provecs Medical, a company formerly active in cancer immunotherapy, a company press release said. The lab is expected to open in April 2020 and will increase the company’s capacity for diagnostic testing of rare genetic diseases along with its COVID-19 capabilities.
"The opening of our lab in Hamburg will significantly contribute to the scaling and success of our COVID-19 testing initiative,” said Dr. Arndt Rolfs, CEO, Centogene, in the press release. “Once we have overcome the challenges of this pandemic and returned to a sense of normalcy, we will further equip our labs in order to continue to strengthen our commitment to rare disease patients around the world â offering transformational medical solutions."
Source: Centogene
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
